Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelmastobart + Paclitaxel in R/R ES-SCLC
NCT06016270Phase 2Terminated
- Sponsor
- STCube
- Start
- Feb 2024
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of nelmastobart in small cell lung cancer (SCLC), sponsored by STCube. Started Feb 2024; status: terminated.
02
Drugs
nelmastobart
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06016270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06016270.